Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 4/20 | 0.38 |
| ▸ | RARG | P13631 | 4/20 | 0.38 |
| ▸ | RARA | P10276 | 3/20 | 0.36 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.36 |
| ▸ | GRM3 | Q14832 | 3/20 | 0.34 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24234509 | 0.89 | PTPN11 (0.41) | CA1CA2PTPN11CYP2D6CYP2C19 | |
| SCHEMBL3019877 | 0.78 | FFAR1 (0.46) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL29997540 | 0.77 | MMP13 (0.34) | MMP13 | |
| SCHEMBL24234516 | 0.76 | — | — | |
| SCHEMBL13245197 | 0.74 | FFAR1 (0.46) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL3022123 | 0.73 | FFAR1 (0.45) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL24234513 | 0.73 | MMP13 (0.32) | MMP13 | |
| SCHEMBL16843077 | 0.72 | RARB (0.38) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL16921533 | 0.72 | RARB (0.41) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL2679567 | 0.72 | TSHR (0.60) | RARBRARGRARACYP26A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827612-B2 | Hydroxamic acid derivative, method for producing same and use thereof | INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2023-11-28 | — | — | US | disclosed |
| US-11827612-B2 | Hydroxamic acid derivative, method for producing same and use thereof | INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2023-11-28 | — | — | US | disclosed |
| EP-4071134-A1 | HYDROXAMIC ACID DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences (CN) | 2022-10-12 | — | — | EP | disclosed |
| US-20220033369-A1 | HYDROXAMIC ACID DERIVATIVE, METHOD FOR PRODUCING SAME AND USE THEREOF | INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033369-A1 | HYDROXAMIC ACID DERIVATIVE, METHOD FOR PRODUCING SAME AND USE THEREOF | HACL2, NAAA, LCT | RARB 2872/4885RARG 2930/4885RARA 2598/4885 |
| US-11827612-B2 | Hydroxamic acid derivative, method for producing same and use thereof | HACL2, NAAA, LCT | RARB 2872/4885RARG 2930/4885RARA 2598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.